Home>10th Plasma Product Biotechnology Conference Review

Overcoming Bottlenecks

Conference Review of 10th Plasma Product Biotechnology

Recently, an international group of plasma fractionators met at the 10th Plasma Product Biotechnology Meeting to discuss the latest developments in plasma-derived therapeutic production including manufacturing, regulatory affairs, and technical process innovations.

The following MilliporeSigma presentations at the forum focused on Immunoglobulin (IgG), the driver of the plasma industry, the switch to subcutaneous administration and increasing regulatory requirements on isoagglutinin.

Craig Jackson MilliporeSigma

High Viscosity Tangential Flow Filtration (TFF) Applications in IgG


Craig Jackson, Senior Product Manager

Current trends in the bioprocessing industry are driving plasma producers to formulate at higher protein concentrations. As a result, formulating using tangential flow filtration (TFF) may be limited in reaching these concentrations due to high pressures caused by highly viscous feed streams. Filtration devices used during processing must be optimized in order to handle both high viscosity and pressures while maintaining high flux and excellent product recovery.

Watch this webinar for more information about a recent study of filtration devices that can overcome process limitations due to high viscosity formulations.

Discover Pellicon® Ultrafiltration Cassettes for higher concentration proteins

Santosh B. Rahane MilliporeSigma

Affinity Resins for Removal of Anti-A
and Anti-B Isoagglutinin


Santosh B. Rahane, Ph.D, Senior Research Scientist

Trace amount of anti-A and anti-B can lead to serious side effects in patients receiving IgG treatments, and can be lethal in severe cases. Anti-A and anti-B clearance from final IgG products may be even more critical for higher concentrations.

To specifically target the removal of anti-A and anti-B isoagglutinin antibodies from plasma-derived IgG therapeutics, two new affinity resins have been developed. These resins use MilliporeSigma’s proprietary base matrix to remove trace amount of ABO blood typing antibodies, anti-A and anti-B.

Contact us for further information on this new technology

We are Now One

EMD Millipore + Sigma-Aldrich =
MilliporeSigma

The life science business of
Merck KGaA, Darmstadt, Germany

Plasma Purification Solutions
Mercrobe EMD Millipore

To learn more about our purification solutions in plasma-derived therapeutics, visit the Plasma Learning Center.